ArticleOncology letters2018
Prognostic value of glypican-1 for patients with advanced pancreatic cancer following regional intra-arterial chemotherapy.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- Glypican-1: a modulator of neurodegenerative and tumorigenic pathways.Frontiers in neuroscience · 2026Article
- Proteomics in pancreatic cancer.Biomarker research · 2025Review
- Glypican-3 and Cytokeratin-19 Expression in Pancreatic Cancer in a Canadian Population.Journal of clinical medicine · 2024Article
- Potential clinical applications of extracellular vesicles in pancreatic cancer: exploring untapped opportunities from biomarkers to novel therapeutic approaches.Extracellular vesicles and circulating nucleic acids · 2024Review
- Evaluation of antitumor potential of an anti-glypican-1 monoclonal antibody in preclinical lung cancer models reveals a distinct mechanism of action.Exploration of targeted anti-tumor therapy · 2024Article
- Review
- Identification of exosome protein panels as predictive biomarkers for non-small cell lung cancer.Biological procedures online · 2023Article
- Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.Oncotarget · 2023Article
- The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection.Mass spectrometry reviews · 2023Review
- Progress on diagnostic and prognostic markers of pancreatic cancer.Oncology research · 2023Review
- Review
- Exosomal glypican-1 is elevated in pancreatic cancer precursors and can signal genetic predisposition in the absence of endoscopic ultrasound abnormalities.World journal of gastroenterology · 2022Article
- Extracellular vesicle-mediated crosstalk between pancreatic cancer and stromal cells in the tumor microenvironment.Journal of nanobiotechnology · 2022Review
- GPC1 Is Associated with Poor Prognosis and Treg Infiltration in Colon Adenocarcinoma.Computational and mathematical methods in medicine · 2022Article
- Extracellular vesicles in pancreatic cancer progression and therapies.Cell death & disease · 2021Review
- Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.BMC cancer · 2021Article
- Current State of "Omics" Biomarkers in Pancreatic Cancer.Journal of personalized medicine · 2021Review
- EGFR-Dependent Extracellular Matrix Protein Interactions Might Light a Candle in Cell Behavior of Non-Small Cell Lung Cancer.Frontiers in oncology · 2021Review
- The evolving translational potential of small extracellular vesicles in cancer.Nature reviews. Cancer · 2020Review
- The biologyScience (New York, N.Y.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regional intra-arterial chemotherapy (RIAC) is a potential alternative treatment for advanced pancreatic cancer (APC) with fewer adverse effects than other treatment options. However, specific biomarkers to determine the prognosis of patients with APC have thus far, been unsatisfactory. Glypican-1 (GPC1) in exosomes has been identified as an early diagnostic biomarker for pancreatic adenocarcinoma. The aim of the present study was to investigate whether the presence of GPC1 in extracellular vesicles (EVs) could serve as a predictor of RIAC outcome for patients with APC. EVs in circulation were isolated and the percentage of GPC1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.